AIM - AIM Immunotech completes all treatments in early-stage ampligen study

AIM ImmunoTech (AIM) announces that all subjects have completed treatment in the company’s Phase 1 clinical study to assess the safety, tolerability and biological activity of ampligen as a potential intranasal therapy.Shares up more than 3% premarket.The company said that a final study report is expect in the third quarter of 2021.A total of 40 healthy subjects received either Ampligen or a placebo in the trial, with the Ampligen given at four escalating dosages across four cohorts, to a maximum level of 1,250 micrograms. AIM highlighted that the study reported no Severe Adverse Events at any dosage level.With the positive preliminary results, the company is now moving forward with the initial planning and negotiations for a follow-up Phase 2 study testing ampligen as a potential broad-spectrum respiratory virus prophylaxis.The company had completed dosing of Cohort 3 in a Phase 1 study of Ampligen as an intranasal therapy, as a potential prophylaxis or treatment for COVID-19 and

For further details see:

AIM Immunotech completes all treatments in early-stage ampligen study